Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A research team led by Prof Alison Simmons at MRC Human Immunology Unit used single-cell technology to identify new players in the gut epithelial barrier.

Inflammatory Bowel Disease (IBD) is a disease that affects at least 300,000 people in the UK alone. Its incidence is increasing worldwide, in particular in industrial-urbanised societies. There is no cure for IBD, and while many patients can manage the symptoms with appropriate care, approximately 40% of patients do not respond to available therapies.

Diseases such as IBD develop when the symbiotic relationship between the cells lining the surface of the gut wall and the trillions of bacteria that live inside the gut lumen breaks down. Normally these bacteria are beneficial to our bodies, helping to digest food, training the immune system or preventing harmful bacteria from taking hold. However, in diseases such as IBD, the barrier cell layer that keeps these microorganisms inside the gut lumen breaks down, leading to emergence of harmful bacteria and subsequent inflammation.

Read more (MRC Weatherall Institute of Molecular Medicine website)

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.